FLAVORx rolls out iPhone app
FLAVORx aims to help improve adherence to pediatric medications with the launch of its first mobile application for iPhone.
Supplier News
Topical BioMedics plans more MyPainAway products
Topical BioMedics Inc. is building on its Topricin topical pain relief brand with MyPainAway powered by Topricin, a product line extension. The company said products in the new line address specific ailments and pain issues.
Daymon Worldwide names new CEO
Jim Holbrook has been appointed as chief executive officer at Daymon Worldwide, succeeding Carla Cooper, who is retiring. The consumables retail marketing firm said Thursday that Holbrook is slated to take the helm as CEO on Sept. 1. He also will join Daymon’s board of directors.
AmerisourceBergen creates nonprofit foundation
AmerisourceBergen Corp. has launched the AmerisourceBergen Foundation, a nonprofit charitable organization that provides grants to health- and pharmaceutical-related causes and educational opportunities.
Aurobindo cleared to market Xanax generic
Aurobindo Pharma Ltd. has gained Food and Drug Administration approval for alprazolam tablets, a medication for anxiety. Aurobindo said its alprazolam product — available in dosages of 0.25 mg, 0.5 mg, 1 mg and 2 mg — is a generic version of Xanax tablets from Pfizer Inc. Part of a group of
Hershey extends Brookside line with fruit & nut bars
Hershey Co. is expanding its Brookside wholesome snack brand with the addition of Brookside Fruit & Nut Bars. Hershey said Tuesday that the new offering builds on the success of Brookside Dark Chocolates.
DenTek launches e-commerce website
DenTek has gone live with a new branded website featuring full e-commerce capabilities. The oral care brand said Monday that DenTek.com now provides oral care product information and tips plus the ability for consumers to buy items directly through the site.
Pfizer to buy U.S. rights for potential MS generic drug
Pfizer Inc. has entered into an agreement with Synthon to acquire the exclusive U.S. commercialization rights for glatiramer acetate, a potential generic version of Teva Pharmaceuticals’ Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS).
Hikma to buy Roxane for $2.65 billion
Hikma Pharmaceuticals PLC, a fast growing multinational pharmaceutical group, plans to acquire Roxane Laboratories from Boehringer Ingelheim in a deal valued at $2.65 billion. Hikma said the agreement stands to transform its position in the U.S.
Par ships authorized generic of Megace ES
Par Pharmaceutical Companies Inc. has released an authorized generic version of Par Specialty Pharmaceutical’s Megace ES oral suspension.
Unilever, Walgreens team up to help families in need
Unilever and Walgreens have partnered with Me to We to provide customers with a way to make a positive impact on the world through everyday purchases.
Stopain Migraine to hit shelves at Rite Aid, H-E-B
Troy Healthcare is expanding retail distribution of its Stopain Migraine topical pain reliever, which a recent study found to be safe and effective in treating an acute migraine attack.
P&G names Taylor as next CEO
David Taylor, Procter & Gamble Co.’s group president of global beauty, grooming and health care, has been chosen to succeed A.G. Lafley as the company’s president and chief executive officer. P&G said late Tuesday that Taylor is slated to take the helm as CEO on Nov.
Brush Buddies rolls out Soniclean Pro One
A new sonic toothbrush from Brush Buddies brings consumers a “fresh-out-of-the-dentist clean feeling at drug store prices,” the company said.
Sandoz releases Pulmicort Respules generic
Sandoz has launched budesonide inhalation suspension, an asthma medication, in the U.S. market. The Novartis subsidiary said Tuesday that it will market its budesonide inhalation suspension in 1-mg strength, and it expects 180-day generic drug marketing exclusivity for that dosage.
Teva to buy Allergan Generics for $40.5 billion
Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.